### Targeting Solid Tumors with IMA402, a Next-generation Bispecific T Cell Engaging Receptor (TCER) against PRAME

**S. Missel**, S. Burk*, M. Hofmann*, G. Pszolla†, M. Hutt*, F. Schwoebel†, F. Unverdorben†, N. Aschmoneit†, C. Wagner†, M. Jaworski†, H. Schuster†, F. Schwoerer†, C. Schraeder†, O. Schoor†, N. Hilf†, T. Weinschenk‡, D. Maurer†, C. Reinhardt‡

**1**Immunatics Biotechnologies GmbH, Tuebingen, Germany, **2**Immunatics N.V., Tuebingen, Germany

---

**The Next-generation of TCR Bispecifics – TCER**

The use of T cell engaging bispecifics redirecting T cells towards human leukocyte antigens (HLA)-presented peptides is emerging as a promising treatment modality for patients with solid tumors. Improving drug safety, efficacy and dosing schedules are key considerations for the generation of optimized bispecific moieties. Here, we present preclinical data for our next-generation T cell engaging receptor (TCER) candidate IMA402 targeting an HLA-A*0201-presented peptide derived from PRAME, which is highly prevalent across multiple solid tumors.

**TCER Format Is Designed for Optimized Efficacy and Safety**

TCER molecules are designed with a high affinity TCR and a low-affinity T cell recruiting Ab to optimize biodistribution*.

---

**IMA402 Shows Tumor Cell Killing at Low PRAME Peptide Levels in vitro**

- **TCER IMA402 induces killing of tumor cells with PRAME target copies as low as 50 CpCs**
- **Phenotypic PRAME levels detected in majority of cancer tissues from patients are 100 – 1000 CpCs**

---

**IMA402 Achieves Durable Tumor Control of Large Tumors in vivo**

- **Dose-dependent efficacy of IMA402 in cell-line derived in vivo mouse model**
- **Durable shrinkage of large tumors including complete responses over prolonged period**
- **Sufficiently high drug doses are key to achieving desired anti-tumor effect**

---

**TCER Format Is Designed for Optimized Efficacy and Safety**

Proprietary TCER format consisting of three distinct elements designed for optimal efficacy and minimal toxicity risk in patients.

**TCER binds to targets, recruits and activates T cells and initiates tumor cell killing**

---

**Safety Assessment Confirms Favorable Safety Profile**

- **Proprietary TCER format supports very low toxicity risk and minimal toxicity risk in patients**
- **Sufficiently high drug doses are key to achieving desired anti-tumor effect**

---

**In vivo Safety Assessment Confirms Favorable Safety Profile**

- **Low toxicity in acute toxicity studies**
- **No histological toxicities upon 5x therapeutic dose**
- **No anti-tumor activity of IMA402 with high 1000-fold excess**

---

**Half-life Extended Format of IMA402 Confers Terminal Half-life of >1 Week in Mice**

- **Half-life Extended Format of IMA402 confers terminal half-life of \(>1\) week in mice**
- **IMA402 shows a terminal serum half-life of \(>8\) days in mice**
- **IMA402 will be initially dosed weekly in the clinical trial**
- **Dosing frequency may be adapted based on clinical data**

---

**TCR IMA402 – Next-generation TCR Bispecific Targeting PRAME**

- **IMA402 is a next-generation, half-life extended TCR Bispecific directed against PRAME demonstrating enhanced anti-tumor activity, reduced T cell engager-associated toxicities and favorable pharmacodynamic characteristics in preclinical studies**
- **TCER format is optimized for efficacy and safety**
- **IMA402 using a low-affinity T cell recruiting antibody shows superior tumor control compared to analogous TCR molecules designed with higher-affinity cytolytic antibodies used in safety and antibody receptor**
- **IMA402 is optimized for reducing T cell engager-associated toxicities in patients, which is demonstrated by a reduced recruiting antibody-mediated cytokine release in vitro**

---

**Phase 1/2 Clinical Trial to Start in 2023**

- **IMA402 Phase 1/2 Clinical Trial to Start in 2023**
- **CNC and supply activities on track for clinical trial**
- **Manufacturing process development completed**
- **High (>1·5 g) and good stability allowing liquid formulation**

---

**Contact information:** info@immatics.com

---

**ACKNOWLEDGEMENTS:** The authors acknowledge significant contributions of the IMN team for TCR and supply activities for the antibody drug, the clinicians for trial design and Sabina Schwer for significant support in preparation of this paper.